Susan Snow
About Susan Snow
Susan Snow is an independent director of Creative Medical Technology Holdings, Inc. (CELZ) since December 2021, serving as Audit Committee Chair and Corporate Governance & Nominating Committee Chair, and a member of the Compensation Committee; she is designated by the Board as an “audit committee financial expert.” She previously earned her CPA at KPMG, held CFO roles in private industry, served as Senior VP, Operations at Redhorse (2018–2022), and was a principal at Transitional Finance Partners (2009–2018); she has been a director at NeoVolta Inc. since July 2022. Ms. Snow is age 68 per the company’s director table and is considered independent under Nasdaq standards through committee independence determinations .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Redhorse | Senior Vice President, Operations | Jan 2018 – Jan 2022 | Government-focused consulting operations leadership |
| Transitional Finance Partners | Principal | May 2009 – Jan 2018 | Finance and corporate advisory |
| KPMG | Early career; earned CPA | ~4 years (early career) | Foundation in audit/accounting; CPA credential |
| Private industry | Chief Financial Officer | Not specified | Corporate finance leadership roles |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| NeoVolta Inc. | Director | Since July 2022 | Committee roles not disclosed |
Board Governance
- Independence and roles: Snow chairs Audit and Corporate Governance & Nominating, and is a member of Compensation; the Board determined committee members meet SEC/Nasdaq independence requirements, and designated Snow as an “audit committee financial expert.” The Board has three independent directors overall .
- Board leadership: CEO serves as Chair; no Lead Director, with risk oversight described at the board level .
- Attendance: Each director attended at least 75% of Board and applicable committee meetings; Board met 5 times in 2023 and 8 times in 2024 .
| Governance Element | 2023 | 2024 |
|---|---|---|
| Board meetings held | 5 | 8 |
| Director attendance threshold | ≥75% (each director) | ≥75% (each director) |
| Lead Independent Director | None | None |
| Audit Committee | Snow (Chair); Urdang; Finger | Snow (Chair); Urdang; Finger |
| Compensation Committee | Urdang (Chair); Snow; Finger | Urdang (Chair); Snow; Finger |
| Corp. Governance & Nominating Committee | Snow (Chair); Urdang; Finger | Snow (Chair); Urdang; Finger |
| Audit committee financial expert | Snow | Snow |
Fixed Compensation
- Program: Non-employee directors receive an annual retainer of $80,000 plus $20,000 for each committee they chair; amounts may be paid in a combination of cash and stock .
- Fees: Snow received $120,000 in fees in 2023 and $120,000 in 2024; no option awards or other compensation disclosed .
| Component ($) | 2023 | 2024 |
|---|---|---|
| Annual retainer | $80,000 (program terms) | $80,000 (program terms) |
| Committee chair fees | $40,000 (two chairs at $20k each, program terms) | $40,000 (two chairs at $20k each, program terms) |
| Fees earned (reported) | $120,000 | $120,000 |
| Option awards | $0 | $0 |
| All other compensation | $0 | $0 |
| Total | $120,000 | $120,000 |
Performance Compensation
- No director performance-based equity awards or metrics were disclosed; option awards for Snow were $0 in both 2023 and 2024 .
| Performance Metric | 2023 | 2024 |
|---|---|---|
| Stock/option awards tied to performance | Not disclosed; option awards $0 | Not disclosed; option awards $0 |
| TSR/financial targets for director pay | Not disclosed | Not disclosed |
Other Directorships & Interlocks
| Company | Relationship to CELZ | Director | Notes |
|---|---|---|---|
| NeoVolta Inc. | External company | Snow | Serving as director since July 2022; no interlocks disclosed with CELZ counterparties |
Expertise & Qualifications
- CPA and audit background (KPMG), CFO experience in private industry, senior operating leadership, and finance expertise; designated audit committee financial expert and financially sophisticated under Nasdaq .
Equity Ownership
- Beneficial ownership: As of Oct 29, 2025, Snow beneficially owned “-0-” shares; ownership for each director shown as less than 1%. Outstanding shares at that date were 2,850,930 .
| As of | Shares Beneficially Owned | Ownership % | Reference Base |
|---|---|---|---|
| Oct 29, 2025 | 0 | <1% (“*”) | 2,850,930 shares outstanding |
Insider Trades and Section 16 Compliance
| Year | Section 16(a) Delinquent Filings | Note |
|---|---|---|
| 2023 | None reported for directors/officers/≥10% holders | Based on Forms 3/4 review |
| 2024 | None reported for directors/officers/≥10% holders | Based on Forms 3/4 review |
Related Party Transactions Exposure
- Policy: Related-Person Transactions Policy requires Audit Committee review/approval for transactions >$25,000 with related persons; directors must recuse if interested .
- Disclosed transactions: Historical transactions with affiliates/former directors (StemSpine Patent Purchase with CMH; Jadi Cell license; Narkeshyo LLC research tools purchase) were summarized; no transactions involving Snow were disclosed .
Governance Assessment
- Strengths
- Independent director leading two core committees (Audit; Corporate Governance & Nominating) and designated audit committee financial expert, supporting board oversight of reporting, controls, and governance .
- Attendance at least 75% in 2023 and 2024 with active committee service; board increased meeting cadence in 2024 to eight meetings, indicating engagement during a period of financing and special approvals .
- Concerns / RED FLAGS
- No personal share ownership as of Oct 29, 2025, which weakens “skin‑in‑the‑game” alignment for a governance lead (RED FLAG) .
- Combined CEO/Chair and no Lead Director, which can constrain independent oversight; Snow’s committee leadership partly mitigates but remains a governance weakness .
- Company history of related‑party arrangements with affiliates/former directors underscores the importance of rigorous Audit Committee monitoring; Snow’s role as Audit Chair is consequential for investor confidence .
- Compensation Alignment
- Director pay is cash-heavy with chair stipends; no equity awards disclosed for Snow in 2023/2024, limiting long-term alignment despite permissible stock settlement under the program .
- Net Implication
- Governance effectiveness hinges on Snow’s continued independent leadership of Audit and Governance committees; lack of equity ownership and the board’s leadership structure warrant ongoing monitoring, particularly around related-party oversight, financing actions (e.g., inducement warrants), and control environment disclosures .